<![CDATA[Biotek-snakken — Marts 2022]]>Godmorgen...

]]>https://dev.proinvestor.com/forum/topic/401417/biotek-snakken-marts-2022RSS for NodeSat, 06 Jun 2026 21:03:48 GMTTue, 01 Mar 2022 06:40:12 GMT60<![CDATA[Reply to Biotek-snakken — Marts 2022 on Thu, 31 Mar 2022 05:32:11 GMT]]>"Danske" IGM Bioscience laver flot aftale med Sanofi. 6 targets/$6B dev/reg milestone med 50/50 rev split på oncology targets. Oppe 70% https://kvgo.com/2022-oncology-conference/igm-biosciences-inc-feb

]]>https://dev.proinvestor.com/forum/post/8064574https://dev.proinvestor.com/forum/post/8064574Thu, 31 Mar 2022 05:32:11 GMT<![CDATA[Reply to Biotek-snakken — Marts 2022 on Thu, 31 Mar 2022 03:42:16 GMT]]>Carlsberg exit, Tesla stigning og bund i biotek? https://www.proinvestor.com/boards/102571

]]>https://dev.proinvestor.com/forum/post/8064576https://dev.proinvestor.com/forum/post/8064576Thu, 31 Mar 2022 03:42:16 GMT<![CDATA[Reply to Biotek-snakken — Marts 2022 on Thu, 31 Mar 2022 02:48:27 GMT]]>Godmorgen...

]]>https://dev.proinvestor.com/forum/post/8064570https://dev.proinvestor.com/forum/post/8064570Thu, 31 Mar 2022 02:48:27 GMT<![CDATA[Reply to Biotek-snakken — Marts 2022 on Wed, 30 Mar 2022 06:55:53 GMT]]>Cantargia: Redeye ude med nu opdatering for Cantargia for de som skulle være interesserethttps://www.redeye.se/research/837273/closing-in-on-a-licensing-deal?utm_source=report&utm_medium=email

]]>https://dev.proinvestor.com/forum/post/8064569https://dev.proinvestor.com/forum/post/8064569Wed, 30 Mar 2022 06:55:53 GMT<![CDATA[Reply to Biotek-snakken — Marts 2022 on Wed, 30 Mar 2022 05:56:02 GMT]]>Jeg tror ikke der er ret meget mere i den aktie...

]]>https://dev.proinvestor.com/forum/post/8064568https://dev.proinvestor.com/forum/post/8064568Wed, 30 Mar 2022 05:56:02 GMT<![CDATA[Reply to Biotek-snakken — Marts 2022 on Wed, 30 Mar 2022 02:54:11 GMT]]>Godmorgen...

]]>https://dev.proinvestor.com/forum/post/8064575https://dev.proinvestor.com/forum/post/8064575Wed, 30 Mar 2022 02:54:11 GMT<![CDATA[Reply to Biotek-snakken — Marts 2022 on Tue, 29 Mar 2022 23:51:35 GMT]]>Bad one on Saniona; https://news.saniona.com/news-releases/news-release-details/saniona-announces-strategic-program-prioritization-and

]]>https://dev.proinvestor.com/forum/post/8064567https://dev.proinvestor.com/forum/post/8064567Tue, 29 Mar 2022 23:51:35 GMT<![CDATA[Reply to Biotek-snakken — Marts 2022 on Tue, 29 Mar 2022 15:14:36 GMT]]>
Just a moment...

favicon

(www.fiercebiotech.com)

]]>https://dev.proinvestor.com/forum/post/8064571https://dev.proinvestor.com/forum/post/8064571Tue, 29 Mar 2022 15:14:36 GMT<![CDATA[Reply to Biotek-snakken — Marts 2022 on Tue, 29 Mar 2022 15:14:31 GMT]]>ImmunoGen files

]]>https://dev.proinvestor.com/forum/post/8064573https://dev.proinvestor.com/forum/post/8064573Tue, 29 Mar 2022 15:14:31 GMT<![CDATA[Reply to Biotek-snakken — Marts 2022 on Tue, 29 Mar 2022 01:15:33 GMT]]>Godmorgen...

]]>https://dev.proinvestor.com/forum/post/8064562https://dev.proinvestor.com/forum/post/8064562Tue, 29 Mar 2022 01:15:33 GMT<![CDATA[Reply to Biotek-snakken — Marts 2022 on Mon, 28 Mar 2022 07:07:58 GMT]]>SUTRO har jo data for pts med prior Bev, og kan se om der er noget om snakken. Er det sandt, kan vi måske forvente at de udvider antal af pts i expansion cohort for at få flere näive Bev pts med i trial ?

]]>https://dev.proinvestor.com/forum/post/8064565https://dev.proinvestor.com/forum/post/8064565Mon, 28 Mar 2022 07:07:58 GMT<![CDATA[Reply to Biotek-snakken — Marts 2022 on Mon, 28 Mar 2022 07:04:36 GMT]]>SUTRO - er det ikke muligt at faldet forleden er udtryk for skepsis til FRa som target pga SORAYA og resultatet (andre mislykkede trials) samtidigt med at Bev gives skylden for kort PFS, som STR002 har et combo studie med. STRO-002 havde 70% prior Bev pts med i dose esc. og 63% prior Bev i dose exp. Har desværre ikke indsigt i Bev indvirken på PFS. Vi kan jo håbe på at det bare en dårligt undskyldning for at mirv ikke er super godt. idk ?

]]>https://dev.proinvestor.com/forum/post/8064566https://dev.proinvestor.com/forum/post/8064566Mon, 28 Mar 2022 07:04:36 GMT<![CDATA[Reply to Biotek-snakken — Marts 2022 on Mon, 28 Mar 2022 04:33:42 GMT]]>SynAct vil hente millioner på aktieemission https://proinvestor.com/investornyt/801047/synact-vil-hente-millioner-pa-aktieemission

]]>https://dev.proinvestor.com/forum/post/8064563https://dev.proinvestor.com/forum/post/8064563Mon, 28 Mar 2022 04:33:42 GMT<![CDATA[Reply to Biotek-snakken — Marts 2022 on Mon, 28 Mar 2022 03:50:01 GMT]]>Biotech Stocks Facing FDA Decision In April 2022 https://proinvestor.com/investornyt/801042/biotech-stocks-facing-fda-decision-in-april-2022

]]>https://dev.proinvestor.com/forum/post/8064560https://dev.proinvestor.com/forum/post/8064560Mon, 28 Mar 2022 03:50:01 GMT<![CDATA[Reply to Biotek-snakken — Marts 2022 on Mon, 28 Mar 2022 02:31:30 GMT]]>Godmorgen...

]]>https://dev.proinvestor.com/forum/post/8064572https://dev.proinvestor.com/forum/post/8064572Mon, 28 Mar 2022 02:31:30 GMT<![CDATA[Reply to Biotek-snakken — Marts 2022 on Sun, 27 Mar 2022 03:29:01 GMT]]>Godmorgen...

]]>https://dev.proinvestor.com/forum/post/8064564https://dev.proinvestor.com/forum/post/8064564Sun, 27 Mar 2022 03:29:01 GMT<![CDATA[Reply to Biotek-snakken — Marts 2022 on Sat, 26 Mar 2022 08:49:47 GMT]]>NBI ved at bunde ud https://www.proinvestor.com/boards/102420/NBI-ved-at-bunde-ud

]]>https://dev.proinvestor.com/forum/post/8064557https://dev.proinvestor.com/forum/post/8064557Sat, 26 Mar 2022 08:49:47 GMT<![CDATA[Reply to Biotek-snakken — Marts 2022 on Fri, 25 Mar 2022 04:52:39 GMT]]>Godmorgen...

]]>https://dev.proinvestor.com/forum/post/8064556https://dev.proinvestor.com/forum/post/8064556Fri, 25 Mar 2022 04:52:39 GMT<![CDATA[Reply to Biotek-snakken — Marts 2022 on Thu, 24 Mar 2022 12:08:30 GMT]]>SUPPORT-ABONNEMENT - Støt Proinvestor.com: https://www.proinvestor.com/donation

]]>https://dev.proinvestor.com/forum/post/8064558https://dev.proinvestor.com/forum/post/8064558Thu, 24 Mar 2022 12:08:30 GMT<![CDATA[Reply to Biotek-snakken — Marts 2022 on Thu, 24 Mar 2022 12:06:25 GMT]]>Kort video: Jeg orienterer om overflytningen af ProInvestor til en ny platform. Der lys forude. :−) I disse tider med krig, rentestigninger osv. kan det være svært at navigere som aktieinvestor. Jeg guider til gode input ift. situationen i Ukraine og Rusland og inspiration til, hvad man kan gøre med sin portefølje i en svær tid, med Hans-Henrik Nielsen fra Markettimer. https://www.proinvestor.com/boards/102348

]]>https://dev.proinvestor.com/forum/post/8064555https://dev.proinvestor.com/forum/post/8064555Thu, 24 Mar 2022 12:06:25 GMT<![CDATA[Reply to Biotek-snakken — Marts 2022 on Thu, 24 Mar 2022 04:35:27 GMT]]>Godmorgen...

]]>https://dev.proinvestor.com/forum/post/8064551https://dev.proinvestor.com/forum/post/8064551Thu, 24 Mar 2022 04:35:27 GMT<![CDATA[Reply to Biotek-snakken — Marts 2022 on Wed, 23 Mar 2022 09:18:02 GMT]]>New data, which at the very least raises question marks about mirvetuximab soravtansine in the eyes of investors, means ImmunoGen could face a bumpy six months.

]]>https://dev.proinvestor.com/forum/post/8064561https://dev.proinvestor.com/forum/post/8064561Wed, 23 Mar 2022 09:18:02 GMT<![CDATA[Reply to Biotek-snakken — Marts 2022 on Wed, 23 Mar 2022 09:17:41 GMT]]>Prior to these latest data, one expert had told FirstWord “so far the only thing we hear are excuses why it is not as good as it should be. It may be only a poor development strategy, but it could also be that the drug is not as good as expected. We’ve also had negative trials with other drugs targeting the folate receptor, which were close to registration but in the end failed. I’m still not convinced of this approach."

]]>https://dev.proinvestor.com/forum/post/8064553https://dev.proinvestor.com/forum/post/8064553Wed, 23 Mar 2022 09:17:41 GMT<![CDATA[Reply to Biotek-snakken — Marts 2022 on Wed, 23 Mar 2022 09:17:10 GMT]]>https://firstwordpharma.com/story/5530631'

]]>https://dev.proinvestor.com/forum/post/8064552https://dev.proinvestor.com/forum/post/8064552Wed, 23 Mar 2022 09:17:10 GMT